4.7 Article

Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia

Journal

NEUROLOGY
Volume 75, Issue 9, Pages 807-814

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f07e0c

Keywords

-

Funding

  1. National Institute of Neurological Disorders and Stroke [NS050641]
  2. Les Turner ALS Foundation
  3. Vena E. Schaff ALS Research Fund
  4. Harold Post Research Professorship
  5. Herbert and Florence C. Wenske Foundation
  6. David C. Asselin MD Memorial Fund
  7. Help America Foundation
  8. Les Turner ALS Foundation/Herbert C. Wenske Foundation Professor
  9. NIH (NINDS) [NS050641, RO1 NS046535, RO1 NS050641]
  10. Avanir Pharmaceuticals
  11. Carolinas ALS Research Fund
  12. Carolinas Healthcare Foundation
  13. NIH (NIEHS) [RO1 ES014469, PO1 ES016742]
  14. Vena Schaaf
  15. Frank White ALS Research Fund
  16. Spastic Paraplegia Foundation, Inc.
  17. Amyotrophic Lateral Sclerosis Association
  18. CVS/ALS Therapy Alliance
  19. Blazeman Foundation for ALS

Ask authors/readers for more resources

Objective: Amyotrophic lateral sclerosis (ALS) is a progressive paralytic disorder caused by degeneration of motor neurons. Mutations in the FUS gene were identified in patients with familial ALS (FALS) and patients with sporadic ALS (SALS) from a variety of genetic backgrounds. This work further explores the spectrum of FUS mutations in patients with FALS and patients with FALS with features of frontotemporal dementia (FALS/FTD) or parkinsonism and dementia (FALS/PD/DE). Methods: All exons of the FUS gene were sequenced in 476 FALS index cases negative for mutations in SOD1 and TARDBP. A total of 561-726 controls were analyzed for genetic variants observed. Clinical data from patients with FUS mutations were compared to those of patients with known SOD1 and TARDBP mutations. Results: We identified 17 FUS mutations in 22 FALS families, 2 FALS/FTD families, and 1 FALS/PD/DE family from diverse genetic backgrounds; 11 mutations were novel. There were 4 frameshift, 1 nonsense, and 1 possible alternate splicing mutation. Patients with FUS mutations appeared to have earlier symptom onset, a higher rate of bulbar onset, and shorter duration of symptoms than those with SOD1 mutations. Conclusions: FUS gene mutations are not an uncommon cause in patients with FALS from diverse genetic backgrounds, and have a prevalence of 5.6% in non-SOD1 and non-TARDBP FALS, and similar to 4.79% in all FALS. The pathogenicity of some of these novel mutations awaits further studies. Patients with FUS mutations manifest earlier symptom onset, a higher rate of bulbar onset, and shorter duration of symptoms. Neurology (R) 2010;75:807-814

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available